Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above 50-Day Moving Average – Should You Sell?

Shares of Interpace Biosciences, Inc. (OTCMKTS:IDXG) passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $6.64 and traded as high as $7.45. Interpace Biosciences shares last traded at $7.00, with a volume of 2,110 shares traded.

Interpace Biosciences Stock Up 22.4%

The company’s 50-day moving average is $6.64 and its two-hundred day moving average is $8.02. The company has a market capitalization of $38.79 million, a P/E ratio of 17.50 and a beta of 0.67.

Interpace Biosciences (OTCMKTS:IDXG) last announced its earnings results on Monday, August 10th. The business services provider reported $0.05 earnings per share (EPS) for the quarter. Interpace Biosciences had a net margin of 67.64% and a return on equity of 145.40%. The business had revenue of $9.13 million during the quarter.

About Interpace Biosciences

Interpace Biosciences, Inc is a molecular diagnostics company focused on improving the diagnosis and management of cancer and other complex diseases. The company develops and commercializes molecular tests that help physicians evaluate disease risk, guide treatment decisions and reduce uncertainty associated with conventional diagnostic procedures.

Its portfolio has included tests for thyroid, pancreatic and gastroesophageal conditions. ThyGeNEXT and ThyraMIR are designed to help evaluate indeterminate thyroid nodules, while PancraGEN supports risk assessment for pancreatic cysts.